Prostate Cancer | Tumor

No Connection Found Between Race and Risk of Skeletal-Related Events or Increased Mortality in Advanced Prostate Cancer

July 9th 2020

Researchers indicate that the current data suggest that race does not have a negative prognostic effect in patients with castration-resistant prostate cancer with bone metastases.

Relumina Appears Superior to Hormone Associated Therapy Leuprolide for Patients with Advanced Prostate Cancer

July 8th 2020

The risk for a major cardiovascular event was reduced by more than half in patients who received Relumina compared to the hormone associated therapy leuprolide.

Turning Clinical Results Into Change for Patients with Prostate Cancer

July 8th 2020

“We don't know what the best treatment paradigm is for a patient whose disease is most clearly manifest on a PSMA scan as opposed to standard imaging,” said Dr. Michael J. Morris. “All that work has yet to be done, and we can only do it once we have the scan available to us as a tool in the United States.”

CURE's Top Stories: June 2020

July 1st 2020

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for June 2020.

ADT May Offer Some Protection From COVID-19 in Men with Prostate Cancer

June 30th 2020

A PCF-funded study of men with prostate cancer in Italy suggests that men with prostate cancer who were taking ADT were 4 times less likely to be infected with the coronavirus than men who were not on ADT (androgen deprivation therapy), and 5 times less likely to die. These new findings are a game-changer and may lead to potential treatments for COVID-19, even in men without prostate cancer.

Looking at Immunotherapies for Patients with Metastatic Prostate Cancer

June 24th 2020

Immunotherapy could help a segment of patients with metastatic prostate cancer, a study found.

Experimental Therapy Shows Promise in Metastatic Castration-Resistant Prostate Cancer

June 11th 2020

“On the basis of these results, (LuPSMA) appears to represent a new class of effective therapy for men with metastatic castration-resistant prostate cancer,” said Dr. Michael S. Hofman.

Nubeqa Reduces Risk of Death, Delays Onset of Chemotherapy in Nonmetastatic Castration-Resistant Prostate Cancer

June 10th 2020

“These results provide compelling evidence for early darolutamide (Nubeqa) treatment in men with nonmetastatic CRPC,” lead study author Dr. Karim Fizazi, said in a virtual presentation during the meeting.

Combination of Cabometyx and Tecentriq Appears Effective in Metastatic Castration-Resistant Prostate Cancer

June 9th 2020

After a median follow-up of 15.8 months, patients within the mCRPC cohort who received the combination achieved an objective response rate of 33%.

Reflecting on COVID-19 as a Person with Cancer

May 25th 2020

FDA's Lynparza Approval Offers Certain Pretreated Patients with Metastatic Prostate Cancer Another Treatment Option

May 22nd 2020

The Food and Drug Administration’s approval of the PARP inhibitor Lynparza for patients with metastatic prostate cancer gives a smaller subgroup of patients another treatment option if hormonal therapies do not work.

FDA Approves Lynparza for Certain Pretreated Patients with Metastatic Prostate Cancer

May 20th 2020

The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).

FDA Approves Rubraca for Metastatic Castration-Resistant Prostate Cancer That Expresses a BRCA Gene Mutation

May 15th 2020

The PARP inhibitor Rubraca represents a new treatment option for men with metastatic castration-resistant prostate cancer that expresses a BRCA gene mutation and has been previously treated with hormonal therapy and taxane-based chemotherapy.

Obesity Linked to Increased Mortality in Prostate Cancer Survivors

May 7th 2020

Obesity was associated with increased cardiovascular disease-related mortality and all-cause mortality, as well as potentially increased prostate cancer-specific mortality, in survivors of nonmetastatic prostate cancer.

Prostate Cancer

May 6th 2020

Understanding prostate cancer.

Lynparza Improves Outcomes in Metastatic Prostate Cancer That Has DNA Repair Defects

May 5th 2020

The PARP inhibitor Lynparza improves survival and delays disease progression in men with metastatic castration-resistant prostate cancer that expresses certain gene mutations inhibiting DNA repair, a study shows.

Molecular Imaging in Prostate Cancer May Help Tailor Treatment for Men with High-Risk Disease

May 5th 2020

An imaging technique known as PSMA PET/CT can detect disease spread at diagnosis more effectively than conventional scans, helping doctors to prescribe appropriate treatments.

Friday Frontline: Cancer Updates, Research and Education on April 3, 2020

April 3rd 2020

From an investigational cancer therapy being studied as a treatment for COVID-19 to the NBA and NHL helping to raise over $500,000 for prostate cancer research, here’s what’s making headlines in the cancer space this week.

Antidepressant Appears Safe, Effective in Men with Biochemical Recurrent Prostate Cancer

March 25th 2020

A medication that is commonly prescribed to treat depression appeared well tolerated in patients with biochemical recurrent prostate cancer.

How to Navigate Cancer in the Wake of the COVID-19 Pandemic

March 20th 2020

Patients with cancer who have routine follow up appointments are being asked to reschedule to help combat the spread of COVID-19.

Exercise Before Androgen-Deprivation Therapy Starts Can Improve Quality of Life in Patients with Prostate Cancer

March 19th 2020

Patients with prostate cancer who were getting ready to receive androgen‐deprivation therapy (ADT) saw sustained improvements in quality of life and their cardiovascular events risk profile after taking part in a supervised exercise program

Prostate Cancer Foundation's COVID-19 Resources

March 16th 2020

Patients with prostate cancer are facing a unique situation amid the COVID-19 pandemic. Here are some of the resources the Prostate Cancer Foundation is offering to help patients in this turbulent situation.

Patients Who Play Active Role in Prostate Cancer Surgery Decisions Less Likely to Experience Regret

March 13th 2020

Decision regret — ranked on a scale of 0 to 100 — was low in patients with localized disease, with a mean score of 14, and there was no significant difference in decision regret between open versus robotic surgery.

Metformin, Statin Combination Reduces Mortality in High-Risk Prostate Cancer

March 6th 2020

Statins alone, and in combination with metformin, are associated with reductions in mortality in patients with high-risk prostate cancer.

Understanding Risks for Breast Implant-Associated Lymphoma

February 20th 2020

Genetic Mutations in Men

February 20th 2020

Laws and Legislation Protecting Those with a Genetic Predisposition

February 20th 2020

Talking About Direct-To-Consumer Genetic Testing

February 20th 2020

Equal Access Health Care May Improve Survival Outcomes Among Men with Prostate Cancer

January 28th 2020

A study of the Veterans Affairs health system found that, despite trends suggesting otherwise, African American men with prostate cancer had similar survival outcomes, compared with non-Hispanic White men.

Vegetable Consumption Does Not Decrease Prostate Cancer Progression

January 19th 2020

Researchers found that men with prostate cancer who consumed a diet high in vegetable did not experience clinical benefit; however, overall health benefits were seen.